Leerink Partnrs Has Positive Estimate for Bruker Q2 Earnings

Bruker Corporation (NASDAQ:BRKR) – Stock analysts at Leerink Partnrs raised their Q2 2026 EPS estimates for shares of Bruker in a report issued on Monday, November 3rd. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn $0.48 per share for the quarter, up from their previous estimate of $0.45. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker’s Q3 2026 earnings at $0.62 EPS, FY2026 earnings at $2.44 EPS and FY2027 earnings at $2.84 EPS.

A number of other research firms also recently issued reports on BRKR. Cowen reiterated a “hold” rating on shares of Bruker in a research report on Tuesday. Wells Fargo & Company cut their target price on shares of Bruker from $50.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday. Barclays increased their target price on shares of Bruker from $40.00 to $45.00 and gave the stock an “overweight” rating in a research report on Tuesday. Stifel Nicolaus set a $40.00 target price on shares of Bruker and gave the stock a “hold” rating in a research report on Tuesday, August 5th. Finally, UBS Group raised their price target on shares of Bruker from $40.00 to $43.00 and gave the company a “neutral” rating in a report on Tuesday. Five equities research analysts have rated the stock with a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $48.30.

Bruker Stock Down 0.4%

BRKR stock opened at $40.20 on Thursday. Bruker has a 12-month low of $28.53 and a 12-month high of $64.64. The company has a quick ratio of 0.70, a current ratio of 1.61 and a debt-to-equity ratio of 1.31. The company has a market cap of $6.10 billion, a price-to-earnings ratio of 77.31, a PEG ratio of 5.31 and a beta of 1.26. The company has a 50 day moving average of $34.78 and a two-hundred day moving average of $37.04.

Bruker (NASDAQ:BRKR) last released its earnings results on Monday, November 3rd. The medical research company reported $0.45 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.33 by $0.12. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The company had revenue of $860.50 million during the quarter, compared to the consensus estimate of $847.40 million. During the same quarter in the prior year, the firm earned $0.60 EPS. The company’s revenue was down .5% compared to the same quarter last year. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS.

Bruker Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, January 2nd. Investors of record on Monday, December 8th will be paid a $0.05 dividend. The ex-dividend date is Monday, December 8th. This represents a $0.20 dividend on an annualized basis and a yield of 0.5%. Bruker’s dividend payout ratio (DPR) is presently -125.00%.

Insider Transactions at Bruker

In related news, Director Cynthia M. Friend sold 3,535 shares of the firm’s stock in a transaction on Friday, September 12th. The shares were sold at an average price of $32.25, for a total value of $114,003.75. Following the transaction, the director directly owned 18,016 shares in the company, valued at approximately $581,016. This trade represents a 16.40% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Insiders own 27.30% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Linden Thomas Advisory Services LLC grew its stake in Bruker by 2.1% in the 3rd quarter. Linden Thomas Advisory Services LLC now owns 19,669 shares of the medical research company’s stock valued at $639,000 after buying an additional 396 shares during the last quarter. Meixler Investment Management Ltd. grew its stake in Bruker by 4.3% in the 3rd quarter. Meixler Investment Management Ltd. now owns 12,983 shares of the medical research company’s stock valued at $422,000 after buying an additional 530 shares during the last quarter. Old West Investment Management LLC grew its stake in Bruker by 144.2% in the 3rd quarter. Old West Investment Management LLC now owns 573,462 shares of the medical research company’s stock valued at $18,632,000 after buying an additional 338,618 shares during the last quarter. Hantz Financial Services Inc. grew its stake in Bruker by 774.8% in the 3rd quarter. Hantz Financial Services Inc. now owns 13,647 shares of the medical research company’s stock valued at $443,000 after buying an additional 12,087 shares during the last quarter. Finally, Atlantic Union Bankshares Corp acquired a new position in Bruker in the 3rd quarter valued at $188,000. 79.52% of the stock is currently owned by institutional investors and hedge funds.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.